Reference is made to Circio Holding ASA's (the "Company") stock exchange
announcement on 9 March 2023, in which the Company announced that it had
requested Atlas Special Opportunities, LLC ("Atlas") to subscribe and pay for
the first tranche of convertible bonds under the Investment Agreement entered
into between Atlas and the Company, consisting of 75 convertible bonds.

Atlas has, by a notice of conversion, requested conversion of convertible bonds
with a nominal value of NOK 2,500,000 which, pursuant to the bond terms, are
convertible into 1,181,009 new shares in the Company at a conversion price of
NOK 2.1168.

The Company's share capital will accordingly be increased by NOK 708,605.40 by
the issuance of 1,181,009 new shares upon completion of the conversion by
registration of the share capital increase in the Norwegian Register of Business
Enterprises (Nw.: Foretaksregisteret). Following the conversion, the Company's
total share capital will be NOK 6,392,893.20 divided into 10,654,822 shares,
each with a nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com (erik.wiklund@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems, and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.